Amneal Pharmaceuticals (AMRX) is back in focus after reporting 2025 results, with revenue of US$3.02b, operating income of US$421m, and lower net leverage of 3.5x, alongside 2026 guidance pointing to adjusted EBITDA and EPS growth.

The recent pullback, including a 16.4% 1 month share price return decline to US$12.39, sits against a much stronger backdrop. The 1 year total shareholder return is 41.9%, and the 3 year total shareholder return is near 8x. This suggests that longer term momentum has been stronger than the latest move.

If Amneal’s update has you thinking about where else growth stories could emerge in healthcare, it may be worth scanning 35 healthcare AI stocks

So with the shares pulling back after a strong multi year run and the stock trading below the average analyst price target, is this a reset that leaves upside on the table, or is the market already pricing in future growth?

Most Popular Narrative: 26.2% Undervalued

With Amneal’s fair value estimate at $16.80 versus a last close of $12.39, the most followed narrative frames the current pullback as leaving a wide valuation gap on the table.

The recent debt refinancing, substantial reduction in annual interest expense, and anticipated tax benefits (from immediate R&D expensing) give Amneal greater financial flexibility to reinvest in high-growth areas and pursue vertical integration of biosimilars, which could further enhance future earnings and free cash flow.

Want to understand why this narrative assigns such a premium to future earnings power? The crux is how revenue growth, margin expansion, and valuation multiples all link back to that fair value. The tension is in how ambitious those assumptions are compared with today’s profitability profile.

Result: Fair Value of $16.80 (UNDERVALUED)

However, this hinges on U.S. generics pricing and leverage, with sustained margin pressure or slower biosimilar and specialty traction both capable of quickly challenging the underpriced narrative.

Another Angle on Valuation

The earlier fair value of $16.80 comes from a cash flow based view, but the current P/E of 54.1x paints a different picture. That multiple is more than double the US Pharmaceuticals industry at 18x and well above a fair ratio of 19.7x, which points to meaningful valuation risk if sentiment cools.

Next Steps

Seen enough to sense both optimism and caution around Amneal? Take a closer look at the underlying data now and weigh the 4 key rewards and 2 important warning signs.

Ready for more investment ideas?

Do not stop your research with a single stock. Broaden your watchlist with other ideas that fit your style before the next move in the market.

• Target potential mispricings by scanning 49 high quality undervalued stocks that combine solid business quality with prices that may not fully reflect their fundamentals.
• Strengthen your focus on resilience by reviewing 73 resilient stocks with low risk scores that score well on stability and balance sheet strength.
• Hunt for fresh opportunities away from the crowd by checking the screener containing 26 high quality undiscovered gems that still fly under most investors' radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.